Abstract: Objective  To analyze the safety and efficacy of ticagrelor in patients with coronary artery disease and chronic obstructive pulmonary disease (COPD). Methods  The clinical trials of ticagrelor versus clopidogrel in patients with coronary artery disease and COPD were searched in domestic and foreign databases which included CNKI,  VIP,  PubMed,  OVID,  web of science. The primary endpoints of this study were the incidence of dyspnea,  bleeding and cardiovascular adverse events in patients with coronary artery disease and COPD. Results  In this study,  7 articles were included. Metaanalysis showed that the incidence of dyspnea was significantly increased in ticagrelor group  compared with clopidogrel group(24.5% vs 13.8%, OR：2.04，95%CI：1.562.66,  P<0.05). However,  ticagrelor group had significant advantages over clopidogrel group in myocardial infarction rate (6.8% vs 10.6%, OR：0.61，95%CI：0.430.87,  P<0.05),  stroke incidence rate (1.1% vs 2.9%,  OR：0.41，95%CI：0.200.84,  P<0.05) and cardiogenic mortality (4.9% vs 8.8%,  OR：0.53，95%CI：0.350.79,  P<0.05). Conclusion  Patients with coronary artery disease and COPD in ticagrelor group had a higher incidence of dyspnea,  but the incidence of cardiovascular adverse events was significantly lower than that of clopidogrel group.

Key words: pulmonary disease, , chronic obstructive, coronary artery disease, ticagrelor, dyspnea, metaanalysis